Eli Lilly’s revenue has soared in recent years thanks to its leadership in the weight loss drug market. Eli Lilly (NYSE: LLY) ...

Eli Lilly & Co. will only work with telehealth firms that agree to stop selling copycat versions of weight-loss drugs, ...

Eli Lilly will be presenting data from studies on multiple GLP-1 drugs later this month. Eli Lilly (NYSE: LLY) stock hasn't ...

Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset. Per ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Compounded GLP-1s are still accessible on telehealth sites, despite an agreement with Eli Lilly to cease copycat sales.

Although as of this week the stock has declined by more than 4% since the start of the year, there's little reason to believe ...

Eli Lilly's growth is impressive, but its current valuation is only justifiable with sustained high growth. Click here to find out why LLY stock is a Hold.

Eli Lilly will partner only with telehealth firms that agree to stop selling compound versions of its drug Zepbound or Novo Nordisk’s Wegovy, a move that sidelines Hims & Hers Health, Bloomberg ...

Companies are always in the race for the top spot, and the only way to achieve it is by reaching a high market valuation. The ...

This proves that Eli Lilly's obesity drug Zepbound, as a GLP-1/GIP agonist, is far more capable of delivering weight loss compared to that of GLP-1 receptor agonist Wegovy. I will be going over ...

The global weight-loss drug market is experiencing exceptional growth, projected to expand from around $144.6 billion in 2023 ...